| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1200/JCO.1986.4.2.234 |
| P698 | PubMed publication ID | 2418169 |
| P2093 | author name string | R Kurzrock | |
| M Talpaz | |||
| J R Quesada | |||
| J U Gutterman | |||
| A Rios | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | toxicity | Q274160 |
| P304 | page(s) | 234-243 | |
| P577 | publication date | 1986-02-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Clinical toxicity of interferons in cancer patients: a review | |
| P478 | volume | 4 |
| Q43035733 | A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C. |
| Q40767749 | A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients |
| Q52010912 | A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. |
| Q35187655 | Acute renal failure during interferon treatment |
| Q54290863 | Acute renal failure with preserved renal plasma flow induced by cancer immunotherapy. |
| Q46884498 | Adverse Events in Cancer Immunotherapy |
| Q78171298 | Another case of focal segmental glomerulosclerosis in an acutely uraemic patient following interferon therapy |
| Q28070279 | Anti-hepatitis C virus drugs and kidney |
| Q32060398 | Anticancer drug-induced kidney disorders |
| Q40745965 | Aseptic meningitis in children: correlation between fever and interferon-gamma level |
| Q50851964 | Associations between physical activity and susceptibility to cancer: possible mechanisms. |
| Q77087590 | Autoimmune hemolytic anemia during alpha-interferon treatment in a patient with chronic myelogenous leukemia |
| Q33413320 | Autoimmune phenomena in lymphoid malignancies. |
| Q33698258 | Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. |
| Q38193573 | Biologic response modifiers and urologic malignancies |
| Q47907417 | Burns in a suicide attempt related to psychiatric side effects of interferon |
| Q72076820 | CHOP-Bleo plus interferon for stage IV low-grade lymphoma |
| Q92202283 | Cancer therapy with major histocompatibility complex-deficient and interferon β-producing myeloid cells derived from allogeneic embryonic stem cells |
| Q33559591 | Cardiomyopathy associated with high-dose interleukin-2 therapy |
| Q69236332 | Cardiovascular rhythm effects of gamma recombinant DNA interferon |
| Q41689551 | Cardiovascular toxicity with cancer chemotherapy |
| Q36589103 | Central Nervous System Toxicity of Biological Response Modifiers |
| Q67931943 | Changes in serum lipids in patients with condylomata acuminata treated with interferon alfa-n1 (Wellferon) |
| Q34609452 | Chemotherapy-associated renal dysfunction |
| Q40995312 | Chronic myelogenous leukemia: a review |
| Q36587700 | Clinical Use of Biologic Response Modifiers in Cancer Treatment: An Overview Part I. The Interferons |
| Q34996327 | Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders |
| Q69926937 | Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma |
| Q41729935 | Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy |
| Q40390091 | Clinical toxicity of the interferons. |
| Q38840254 | Coley's Lessons Remembered: Augmenting Mistletoe Therapy |
| Q43585843 | Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C. |
| Q57462917 | Combination of entecavir/ peginterferon alfa-2a in children with HBeAg-positive immune tolerant chronic hepatitis B virus infection |
| Q71120115 | Combined modality therapy for cutaneous T-cell lymphoma |
| Q40875316 | Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV. |
| Q36861566 | Concise review: cell therapies: the route to widespread adoption |
| Q45877387 | Constant and steady transgene expression of interferon-γ by optimization of plasmid construct for safe and effective interferon-γ gene therapy |
| Q34436506 | Cutaneous T-cell lymphoma. New immunomodulators |
| Q35033232 | Cytokine therapeutics: lessons from interferon alpha |
| Q35622833 | Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. |
| Q40589441 | Cytokine-mediated gene therapy for cancer |
| Q47443294 | Cytokines in Cancer Immunotherapy |
| Q33716410 | Cytokines in immune function and sleep regulation |
| Q69055926 | Cytokines: biological function and clinical use |
| Q48097918 | Design of Insulin-Loaded Nanoparticles Enabled by Multistep Control of Nanoprecipitation and Zinc Chelation |
| Q54228292 | Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia |
| Q41544203 | Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management |
| Q33759628 | Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis |
| Q71344417 | Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-gamma 1 |
| Q50475497 | Effects of interferon-alpha2b on hearing. |
| Q35763133 | Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients |
| Q77372860 | Enhancement of immobility in mouse forced swimming test by treatment with human interferon |
| Q38033590 | Evolving therapeutic paradigms for multiple myeloma: back to the future |
| Q45749202 | Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy |
| Q28296175 | Exercise and multiple sclerosis |
| Q46201864 | Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma |
| Q78849136 | Expression of endocrine autoantibodies in chronic hepatitis C, before and after interferon-alpha therapy |
| Q67918969 | Extended Experience with Recombinant a-2b Interferon with OR Without Hepatic Artery Embolization in the Treatment OF Midgut Carcinoid Tumours A preliminary report |
| Q34566468 | Fatigue in multiple sclerosis |
| Q35094640 | Fatigue in multiple sclerosis: definition, pathophysiology and treatment |
| Q34778946 | Fever and sweats in the patient with advanced cancer |
| Q38202913 | First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies |
| Q72852188 | Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study |
| Q43565256 | Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy |
| Q34051992 | Genetic aspects of inherent B-cell abnormalities associated with SLE and B-cell malignancy: lessons from New Zealand mouse models |
| Q38077918 | Glomerular diseases seen with cancer and chemotherapy: a narrative review |
| Q71775352 | Granulocytopenia after combined therapy with interferon and angiotensin-converting enzyme inhibitors: evidence for a synergistic hematologic toxicity |
| Q33801278 | Hepatitis C virus associated glomerulopathies |
| Q70730515 | Hormonal therapy for metastatic renal cell carcinoma combined androgen and provera followed by high dose tamoxifen |
| Q44330363 | Human interferon-alpha induces immobility in the mouse forced swimming test: involvement of the opioid system |
| Q33169142 | Human leukocyte alpha interferon-induced transient neurotoxicity in children |
| Q41179212 | Hyponatremia related to medical anticancer treatment |
| Q71602239 | Hypothyroidism and arthritis during interferon therapy |
| Q26776096 | Immune Responses Against Classical Swine Fever Virus: Between Ignorance and Lunacy |
| Q73692704 | Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines |
| Q45738176 | Immunoprophylactic strategies against respiratory influenza virus infection |
| Q45126156 | Immunosuppression for myocarditis |
| Q71931101 | Immunotherapy of malignant melanoma |
| Q71629909 | Induction of autoimmune phenomena in patients with chronic hepatitis B treated with gamma-interferon |
| Q40450393 | Interferon Induced Focal Segmental Glomerulosclerosis. |
| Q72789573 | Interferon alfa-2a therapy for extensive perianal and lower extremity hemangioma |
| Q68132914 | Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma |
| Q36549261 | Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature. |
| Q43094927 | Interferon associated retinopathy |
| Q38190337 | Interferon for treatment: the dust settles |
| Q35096775 | Interferon in the treatment of hairy-cell leukemia |
| Q40489879 | Interferon treatment of cutaneous T‐cell lymphoma |
| Q35676400 | Interferon type I receptor-deficient mice have altered disease symptoms in response to influenza virus |
| Q40485713 | Interferon-alpha in malignant and viral diseases. A review |
| Q24634125 | Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain |
| Q40935405 | Interferon-induced acute renal failure: a case report and literature review |
| Q33780949 | Interferon-induced cutaneous necrosis |
| Q67746552 | Interferon-induced reversible acute renal failure with nephrotic syndrome |
| Q34400101 | Interferon-mediated fatigue |
| Q33390973 | Interferon-α increases monocyte migration via platelet-monocyte interaction in murine intestinal microvessels |
| Q40484416 | Interferons and interleukins in metastatic renal cell carcinoma |
| Q40935389 | Interferons and other cytokines in head and neck cancer |
| Q71825079 | Interferon‐γ and tumor necrosis factor‐α suppress both early and late stages of hematopoiesis and induce programmed cell death |
| Q40686744 | Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy |
| Q100416706 | Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer |
| Q48966591 | Investigation of the ototoxic effects of interferon alpha2A on the mouse cochlea |
| Q41865084 | Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test |
| Q74587435 | Is interferon-alpha a neuromodulator? |
| Q34543971 | I’m so tired: biological and genetic mechanisms of cancer-related fatigue |
| Q77850503 | Liposomes as cytokine-supplement in tumor cell-based vaccines |
| Q73589182 | Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects |
| Q73542697 | Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines |
| Q68323240 | Liver failure due to recombinant alpha interferon |
| Q38645739 | Liver injury after aluminum potassium sulfate and tannic acid treatment of hemorrhoids |
| Q50079503 | Long-Term Efficacy and Safety of Interferon Alpha-2a in the Treatment of Chinese Patients with Behçet's Uveitis Not Responding to Conventional Therapy |
| Q41720171 | Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle |
| Q44497309 | Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier |
| Q71969578 | Minimal change glomerulonephritis with reversible proteinuria during interferon α2a therapy for chronic myeloid leukemia |
| Q45871435 | Multiple systemic expression of human interferon-beta in mice can be achieved upon repeated administration of optimized pcTG90-lipoplex |
| Q38262786 | Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma |
| Q28247949 | Neoplastic fever: a neglected paraneoplastic syndrome |
| Q95796733 | Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C |
| Q36855950 | Neurologic Complications of Chemotherapy |
| Q35090145 | Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases |
| Q41527295 | New drugs in essential thrombocythemia and polycythemia vera |
| Q37326848 | Part I: Liver function in oncology: biochemistry and beyond |
| Q48697831 | Permeability of the blood-brain and blood-spinal cord barriers to interferons |
| Q33450059 | Phase I study of recombinant human tumor necrosis factor |
| Q28200207 | Practical management of classical myeloproliferative disorder patients: a clinician's guide |
| Q35060017 | Recovery of normal hematopoiesis after severe bone marrow aplasia induced by interferon-alpha in a patient with chronic myelogenous leukemia |
| Q71025167 | Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older |
| Q35863891 | Retinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literature |
| Q43216328 | Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin |
| Q33866418 | Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. |
| Q33496785 | Risks and benefits of interferon-alpha in the treatment of hepatitis |
| Q67707398 | Role of Interferon in Lethality and Lymphoid Atrophy Induced by Coxsackievirus B3 Infection of Mice |
| Q53161859 | Ruxolitinib treatment in an infant with JAK2+ polycythaemia vera-associated Budd-Chiari syndrome. |
| Q33497526 | Side effects of high-dose interferon therapy for chronic hepatitis C. |
| Q28286274 | Side effects of interferon-alpha therapy |
| Q50524902 | Sudden hearing loss associated with interferon. |
| Q68522047 | Symptom distress. Fatigue |
| Q50584301 | Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. |
| Q61818026 | The Elevated Serum Level of IFN- in Patients with Failed Back Surgery Syndrome Remains Unchanged after Spinal Cord Stimulation |
| Q38621580 | The brain and the immune system: a psychosomatic network |
| Q36577185 | The changing epidemiology of acute renal failure |
| Q36746575 | The effects of HCV infection and management on health-related quality of life |
| Q71315387 | The interferons |
| Q36900332 | The kidney in oncology |
| Q38208932 | The role of interferons in the treatment of malignant neoplasms |
| Q46527056 | The treatment of choroidal neovascular membranes by alpha interferon. An efficacy and toxicity study |
| Q51602445 | The use of gemfibrozil in a patient with chronic myelogenous leukemia to successfully manage retinoid-induced hypertriglyceridemia. |
| Q33979195 | The viral mimic, polyinosinic:polycytidylic acid, induces fever in rats via an interleukin-1-dependent mechanism. |
| Q33499764 | Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia |
| Q42368351 | Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab. |
| Q67598999 | Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha |
| Q34289643 | Tolerability of treatments for viral hepatitis |
| Q26779917 | Treatment of Cancer Pain by Targeting Cytokines |
| Q42116278 | Treatment of malignant metastatic midgut carcinoid tumours with recombinant human alpha2b interferon with or without prior hepatic artery embolization |
| Q81573130 | Validation of the FACT-BRM with interferon-alpha treated melanoma patients |
| Q72936563 | [Autoimmune diseases and treatment with interferon-alpha: review of the literature apropos of a case of hyperthyroidism] |
| Q78658421 | [Interferon-alpha and auto-immunity] |
Search more.